Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
The Design of Disease Modifying Drugs for Alzheimer's Targeting the 3-Hydroxyanthranilate Tryptophan Metabolite
FY 2023-24
Summary
Dementia is a condition marked by the loss of cognitive abilities, which can eventually disrupt a person's daily life and activities. Alzheimer's disease (AD) is the most common cause of dementia. While there have been some recent advancements in AD treatment, with drugs like lecanemab and donanemab showing promise, they have limitations. These drugs are large in molecular size, requiring intravenous administration, and patients need frequent injections, often every 2 to 4 weeks. Moreover, they are very expensive, around US$30,000/year. Thus, finding a drug more cost-effective and smaller in size that can effectively calm the neuroinflammation in AD remains a top priority in the world of medicine.
This project focuses on the design and development of a small and affordable drug to target the immunological aspects of AD. Our research group believes that AD may be an autoimmune disease related to our body's natural defense system. In our earlier research, we discovered a natural compound called 3-hydroxyanthranilic acid (3-HAA), a metabolite of tryptophan (an easily accessible amino acid), that can calm down the harmful inflammation in the brain. We also discovered a drug-like analog of 3-HAA, called furosemide. However, furosemide causes side effects like excessive urination leading to dehydration. We further identified the protein Tex264 as the anti-inflammatory receptor site for both 3-HAA and furosemide. My goal is to design a similar compound that can reach the brain, bind to Tex264 and deliver anti-inflammatory effects without causing side effects like excessive urination. This drug will be not only effective but also affordable, as it can be conveniently administered in pill form. By tackling AD with a smaller, cost-effective solution, we hope to bring relief and brighter prospects to individuals and families affected by this challenging condition.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
496580
Name
Yu Liu
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The Design of Disease Modifying Drugs for Alzheimer's Targeting the 3-Hydroxyanthranilate Tryptophan Metabolite
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Computer-Aided Drug Design; Cytokine; Neuroinflammation; Tryptophan
Abstract
Dementia is a condition marked by the loss of cognitive abilities, which can eventually disrupt a person's daily life and activities. Alzheimer's disease (AD) is the most common cause of dementia. While there have been some recent advancements in AD treatment, with drugs like lecanemab and donanemab showing promise, they have limitations. These drugs are large in molecular size, requiring intravenous administration, and patients need frequent injections, often every 2 to 4 weeks. Moreover, they are very expensive, around US$30,000/year. Thus, finding a drug more cost-effective and smaller in size that can effectively calm the neuroinflammation in AD remains a top priority in the world of medicine.
This project focuses on the design and development of a small and affordable drug to target the immunological aspects of AD. Our research group believes that AD may be an autoimmune disease related to our body's natural defense system. In our earlier research, we discovered a natural compound called 3-hydroxyanthranilic acid (3-HAA), a metabolite of tryptophan (an easily accessible amino acid), that can calm down the harmful inflammation in the brain. We also discovered a drug-like analog of 3-HAA, called furosemide. However, furosemide causes side effects like excessive urination leading to dehydration. We further identified the protein Tex264 as the anti-inflammatory receptor site for both 3-HAA and furosemide. My goal is to design a similar compound that can reach the brain, bind to Tex264 and deliver anti-inflammatory effects without causing side effects like excessive urination. This drug will be not only effective but also affordable, as it can be conveniently administered in pill form. By tackling AD with a smaller, cost-effective solution, we hope to bring relief and brighter prospects to individuals and families affected by this challenging condition.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Yu, Liu
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~